Back to Agenda
Session 9: Conference Highlights
Session Chair(s)
Session Chair Invited
United States
This panel discussion is meant to highlight the challenges and issues with the development of oligonucleotide-based products in general and as brought forth at this conference. The intention is to transform this discussion into action-oriented objectives to address the regulatory and industry issues and challenges affecting us all.
Speaker(s)
Discussant and Panelist: Nonclinical Track
Scott Henry, PhD
Ionis Pharmaceuticals, Inc., United States
Vice President, Nonclinical Development
Discussant and Panelist: Nonclinical Track
Arthur A. Levin, PhD
Avidity Biosciences , United States
CSO
Discussant and Panelist: CMC Track
Daniel Capaldi, PhD
Ionis Pharmaceuticals, Inc, United States
Vice President, Analytical and Process Development
Discussant and Panelist: CMC Track
René Thürmer, PhD
Federal Institute for Drugs and Medical Devices, Germany
Deputy Head of the Unit Pharmaceutical Biotechnology BfArM
Discussant and Panelist: Clinical Track
James D. Thompson, PhD
Quark Pharmaceuticals Inc., United States
Vice President, Pharmaceutical Development
Discussant and Panelist: Clinical Track
Saraswathy V. Nochur, PhD, MSc
Alnylam Pharmaceuticals, United States
Chief Regulatory Officer
Have an account?